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Abstracts / Urological Science 26 (2015) 288e293 289Materials and Methods: Cellular proteins from four pairs of surgically
resected primary bladder cancer tumor and adjacent nontumorous tissue
were extracted for two batches of isobaric tags for relative and absolute
quantitation (iTRAQ) experiments. The DAVID (database for annotation,
visualization and integrated discovery) is used for analysis of dysregulated
proteins. ELISA were employed for validation of candidate tumor markers
in tissues and the age-matched urine specimens from bladder cancer pa-
tients and hernia patients as control were compared.
Results: The iTRAQ experiments identiﬁed a total of 3220 proteins. Seven
differentially expressed proteins were selected as potential bladder cancer
biomarkers for further veriﬁcation. Immunohistochemical analyses
showed signiﬁcantly elevated levels of three proteins- SLC3A2, STMN1, and
TAGLN2- in tumor cells compared with noncancerous bladder epithelial
cells, and suggested that TAGLN2 could be a useful tumor tissue marker for
diagnosis (AUC¼ 0.999). The DAVID analysis revealed three top-ranking
biological processes as involved in extracellular matrix organization,
extracellular structure organization, and oxidation-reduction. ELISA
revealed signiﬁcantly increased urinary levels of both STMN1 and TAGLN2
in bladder cancer subgroups compared with control groups. Urinary
TAGLN2 in bladder cancer samples showed the largest fold change (7.13-
fold), with an AUC value of 0.70 (p < 0.001, n¼ 205).
Conclusion: Our study discovered that TAGLN2 showed the most signiﬁ-
cant over expression in bladder cancer tissues and urine specimens, and
thus represents a potential biomarker for noninvasive screening for
bladder cancer.
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Purpose: The aim of this study is evaluating the detection site of prostate
cancer foci in patients receiving transrectal ultrasound(TRUS) guided 10-
core systemic random biopsy and comparing the relationship between
digital rectal examination and prostatic biopsy. The study ultimately aims
to predict pathological staging of prostate cancer by TRUS-biopsy.
Materials and Methods: Between September 2005 and June 2014, 1314
men received TRUS-guided biopsy were included in this study. Indications
for TRUS guided prostate biopsy were: abnormal digital rectal examination
and/or a serum PSA over 4.0 ng/ml. 701 patients were excluded due to less
than 10 cores or received target biopsy and 68 patients were excluded due
to different machine. Finally, 545 patients underwent at least 10-core
random biopsy protocol by TRUS and 46 of those patients treated with
radical retropubic prostatectomy.
Results: Of the 545 patients, one hundred and ﬁfty-two (27.9%) were
positive for prostate cancer, including 64 of 370 (16.2 %) men with normal
DRE and 88 of 175 (50.3 %) with abnormal DRE. Patients with normal DRE
exhibited younger age (67.9 vs. 71.0 yrs, p¼ 0.007), lower serum PSA(15.7
vs. 25.6 ng/ml, p¼ 0.0032), lower PSA density(0.41 vs. 0.71, p¼ 0.0016),
less positive cores(p¼ 0.022), and less Gleason score(p¼ 0.0006) than
those with abnormal DRE.
46 of those patients treated with radical retropubic prostatectomy,
including 17 men with normal DRE and 29 with abnormal DRE. The
pathological ﬁnding revealed higher number of positive biopsy cores in
advanced staging whether digital ﬁnding was positive or not. For eval-
uating the association of the detection site of prostate cancer foci and
pathological staging, we deﬁned low, intermittent, and high risk group
according to number of positive cores in different locations (lateral,
parasagittal, and apical area). We identiﬁed low risk group with no
positive core. Intermittent risk group means one positive core or 2
positive cores ipsilateral (2S). High risk group means 2 positive cores
contralateral (2C) or number of positive cores more than 3. Otherwise,
we also reclassiﬁed pathological staging into 3 subgroups: pT2a and
pT2b, pT2c, and pT3a at least. The pathological ﬁnding of patient with
low risk group will below pT2c and high-risk group will above pT3.
(p¼ 0.031 in lateral sites, p¼ 0.007 in parasagittal sites, and p¼ 0.023 in
apical sites).Conclusions: In our study, patient with normal digital rectal examination
and PSA elevation received TURS-biopsy has 16% malignancy change. Be-
sides, patients with abnormal digital rectal examination received TURS-
biopsy has 50% malignancy change. Patients with normal DRE exhibited
younger age, lower serum PSA, lower PSA density, less positive cores, and
less Gleason score than those with abnormal DRE. The cancer foci detected
by biopsies of the prostate are equally distributed even subgroup analysis
depending on location of positive cores or prostate size. Prediction of
pathological stage in prostate cancer through TRUS 10-core random biopsy
is available in this study.
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Purpose:MicroRNAs (miRNAs) represent a class of small non-coding RNAs
regulating gene expression by inducing the degradation of RNA or inter-
fering with translation. Aberrant miRNA expression has been described in
several types of cancer in humans. By our pre-set miR array data, we iden-
tiﬁed miR-145 as the most signiﬁcant tumor suppressor mir in urothelial
carcinoma (UC). However, the expression of miR-145 in UC of the upper
urinary tract (UTUC) has not been investigated. This study is conducted to
evaluate the outcome predictive value of miR-145 expression in UTUC.
Materials and Methods: Using a miRNA array (Applied Biosystems) that
included 667 human miRNAs and mammalian RNU6B, we compare the
differentially expressed miRNAs between BFTC909 cell line and paired
UTUC samples. The miR-145 expression levels from 65 UTUC tissues and
the paired adjacent noncancerous tissues were investigated by Real-Time
Reverse Transcriptase PCR assay. In addition, the functional consequences
of miR145 transfection in BFTC909 cells were studied in vitro by MTT,
wound healing, cell migration, cell invasion assays.
Results: In 65 paired tissues, we found that mir-145 expression was
signiﬁcantly decreased in UTUC tissues than in paired adjacent noncan-
cerous tissues. Decreased mir-145 expression was associated with worse
recurrence-free and cancer-speciﬁc survival. In cell line experiments, we
demonstrated that mir145 can inhibit cell proliferation, migration and
invasion in BFTC909 cell line after transfection of miR145 mimics.
Conclusion: Our ﬁndings imply that decreased miR-145 expression is a
potential biomarker to predict clinical outcome of UTUC patients. Further
study is necessary to identify the molecular mechanisms of miR-145
involved in the cancerous processes of UTUC.
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Purpose: To evaluate the anti-metastatic potential of osthole in prostate
cancer cells and xenograft animal model.
Materials andMethods: The PC3 and DU145 human adrogen independent
prostate cancer (AIPC) cell lines were obtained from American Type Cul-
ture Collection for cell assay. PC-3M, a highly metastatic subline derived
from the hepatic metastasis of PC-3 in nude mice, was used for xenograft
